For clinicians and researchers
25th Annual MCI Symposium
MCI in 2027: From Early Detection to Precision Diagnosis and Treatment
- Friday, April 2, 2027
- 9:00 AM - 4:45 PM ET
- Virtual
Registration opens in November
View the program
Program
All times US Eastern · Preliminary, subject to change- 9:00 - 9:10 AMWelcome, introductions, and "MCI 25 Years Later"Ranjan Duara, MD, MRCP, FAANMount Sinai Medical Center
Session I Utility of Plasma Biomarkers in Preclinical and Early AD
Chair: Ronald C. Petersen, MD, PhDMayo Clinic
- 9:10 - 9:20 AMSession introductionSession chair
- 9:20 - 9:45 AMFluid-Based Staging of AD Pathology: p-Tau217 and eMTBR-tau243Suzanne E. Schindler, MD, PhDWashington University School of Medicine
- 9:45 - 10:10 AMPlasma p-Tau217 Prognosis in Normal Cognition and Subjective Cognitive DeclineRachel Buckley, PhDMass General Research Institute
- 10:10 - 10:35 AMInterpreting AD Blood Biomarkers in the Presence of Medical ComorbiditiesMichelle M. Mielke, PhDWake Forest University
- 10:35 - 10:55 AMDiscussionSession chair and Session I faculty
Session II Anti-Amyloid Therapy in Practice
Chair: Bradford C. Dickerson, MDMassachusetts General Hospital
- 10:55 - 11:05 AMSession introductionSession chair
- 11:05 - 11:30 AMOptimizing Patient Selection and Safety in Anti-Amyloid TreatmentStephen Salloway, MD, MSBrown University
- 11:30 - 11:55 AMAmyloid Reaccumulation after Plaque Clearance: Implications for Maintenance TreatmentSpeaker to be announced
- 11:55 AM - 12:20 PMPreventing and Managing ARIA in Clinical Practice: Patient Selection, MRI, and Treatment DecisionsMarwan Sabbagh, MD, FAANBarrow Neurological Institute
- 12:20 - 12:40 PMDiscussionSession chair and Session II faculty
- 12:40 - 1:15 PMLunch
Session III The Therapeutic Horizon
Chair: Adam L. Boxer, MD, PhDUniversity of California, San Francisco
- 1:15 - 1:25 PMSession introductionSession chair
- 1:25 - 1:50 PMCELIA Tau ASO: Phase II and the Path to Phase IIIJeffrey Cummings, MD, ScDChambers-Grundy Center for Transformative Neuroscience, UNLV
- 1:50 - 2:15 PMTrontinemab: From Early Clinical Results to the TRONTIER Phase III ProgramCatherine Mummery, PhD, FRCPUniversity College London
- 2:15 - 2:35 PMPanel discussion: From Promise to Practice. Which Emerging Therapies Are Most Likely to Change the Field?Session chair and Session III faculty
Clinical Workshop Five cases from the clinic
Chair: Douglas Galasko, MDUniversity of California, San Diego
- 2:35 - 2:55 PMCase 1: Plasma p-Tau217 positive but amyloid PET negative. What are the treatment implications?Sterling C. Johnson, PhDUniversity of Wisconsin-Madison
- 2:55 - 3:15 PMCase 2: Amyloid- and tau-positive but cognitively normal. Treat, monitor, or wait?Ranjan Duara, MD, MRCP, FAANMount Sinai Medical Center / Wien Center
- 3:15 - 3:35 PMCase 3: MCI due to probable LATEDavid Wolk, MDUniversity of Pennsylvania
- 3:35 - 3:55 PMCase 4: Amyloid-positive with a Lewy body phenotype. Which pathology is driving the clinical picture?Speaker to be announced
- 3:55 - 4:15 PMCase 5: Anti-amyloid therapy in a patient over 85 with early MCI and APOE ε3/ε4. Treat or not treat?Ryan Townley, MDUniversity of Kansas
- 4:15 - 4:35 PMIntegrated panel discussionWorkshop chair and faculty
- 4:35 - 4:45 PMClosing poll and remarksRanjan Duara, MD, MRCP, FAANMount Sinai Medical Center
Faculty
- Adam L. Boxer, MD, PhDUniversity of California, San FranciscoSession III · Chair
- Rachel Buckley, PhDMass General Research InstituteSession I
- Jeffrey Cummings, MD, ScDChambers-Grundy Center for Transformative Neuroscience, UNLVSession III
- Bradford C. Dickerson, MDMassachusetts General HospitalSession II · Chair
- Ranjan Duara, MD, MRCP, FAANMount Sinai Medical CenterOpening, Clinical Workshop · Case 2, Closing
- Douglas Galasko, MDUniversity of California, San DiegoClinical Workshop · Chair
- Sterling C. Johnson, PhDUniversity of Wisconsin-MadisonClinical Workshop · Case 1
- Michelle M. Mielke, PhDWake Forest UniversitySession I
- Catherine Mummery, PhD, FRCPUniversity College LondonSession III
- Ronald C. Petersen, MD, PhDMayo ClinicSession I · Chair
- Marwan Sabbagh, MD, FAANBarrow Neurological InstituteSession II
- Stephen Salloway, MD, MSBrown UniversitySession II
- Suzanne E. Schindler, MD, PhDWashington University School of MedicineSession I
- Ryan Townley, MDUniversity of KansasClinical Workshop · Case 5
- David Wolk, MDUniversity of PennsylvaniaClinical Workshop · Case 3